Roberto Ranza
Overview
Explore the profile of Roberto Ranza including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
29
Citations
277
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kavanaugh A, Mease P, Gossec L, Ranza R, Tsuji S, Douglas K, et al.
ACR Open Rheumatol
. 2024 Aug;
6(11):736-745.
PMID: 39087872
Objective: We explored the relationship between achievement of clinical disease control and improvements in and normative values for patient-reported outcomes (PROs), including quality of life (QoL) measures, in patients with...
2.
Kwatra S, Khattri S, Amin A, Ranza R, Kaplan B, Shi L, et al.
Dermatol Ther (Heidelb)
. 2024 May;
14(6):1517-1530.
PMID: 38739215
Introduction: The presence (vs absence) of enthesitis/dactylitis is associated with greater psoriatic arthritis (PsA) activity and reduced health-related quality of life. Risankizumab, an interleukin 23 antagonist, demonstrated superior treatment efficacy...
3.
Fernandez-Avila D, Bautista-Molano W, Brance M, Avila Pedretti M, Vargas R, Diaz Coto J, et al.
J Rheumatol
. 2024 Apr;
51(6):563-576.
PMID: 38561190
Objective: Psoriatic arthritis (PsA) is chronic disease that compromises multiple domains and might be associated with progressive joint damage, increased mortality, functional limitation, and considerably impaired quality of life. Our...
4.
Bredemeier M, Duarte A, Pinheiro M, Kahlow B, Macieira J, Ranza R, et al.
Rheumatology (Oxford)
. 2023 May;
63(2):456-465.
PMID: 37216912
Objectives: To test the association of use of antimalarials with the overall safety of treatment in RA patients receiving one or multiple courses of biologic (b)DMARDs or a Janus kinase...
5.
Baraliakos X, Ranza R, Ostor A, Ciccia F, Coates L, Rednic S, et al.
Arthritis Res Ther
. 2023 Apr;
25(1):56.
PMID: 37038159
Background: The objective of this post-hoc analysis was to assess the efficacy and safety of upadacitinib in psoriatic arthritis (PsA) patients with axial involvement. Methods: Post-hoc analysis of SELECT-PsA 1...
6.
Eder L, Mathew A, Carron P, Bertheussen H, Canete J, Azem M, et al.
J Rheumatol
. 2022 Nov;
50(2):258-264.
PMID: 36319005
Objective: Enthesitis is a key pathological and clinical feature of psoriatic arthritis (PsA) in children and adults. Enthesitis is typically assessed clinically using several validated enthesitis scoring systems that have...
7.
Souza C, Goldenstein-Schainberg C, Alvarenga Anti Loduca Lima S, Spelling Gormezano N, Magalhaes R, Ranza R
J Clin Rheumatol
. 2022 Mar;
28(3):120-125.
PMID: 35325900
Objective: The aim of this study was to examine the effect of clinical specialty setting on the management of psoriatic arthritis (PsA) as well as disease activity/burden in Brazil. Methods:...
8.
Bredemeier M, Ranza R, Kakehasi A, Ranzolin A, da Silveira I, Ribeiro A, et al.
J Rheumatol
. 2022 Jan;
49(1):122.
PMID: 34974425
No abstract available.
9.
Strand V, Van den Bosch F, Ranza R, Leung Y, Drescher E, Zueger P, et al.
Rheumatol Ther
. 2021 Oct;
8(4):1827-1844.
PMID: 34661885
Introduction: Psoriatic arthritis (PsA) has a major impact on health-related quality of life (HRQOL) and other patient-reported outcomes (PROs), important components in the assessment of therapeutic efficacy. We evaluated the...
10.
Bredemeier M, Ranza R, Kakehasi A, Ranzolin A, da Silveira I, Ribeiro A, et al.
J Rheumatol
. 2021 May;
48(10):1519-1527.
PMID: 33934077
Objective: To evaluate the safety of the methotrexate (MTX)-leflunomide (LEF) combination in rheumatoid arthritis (RA), comparing it with other therapeutic schemes involving conventional synthetic (cs-) and biologic (b-) disease-modifying antirheumatic...